Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan)

Clinical Cancer Research

Volumn 21, Issue 22, 2015, Pages 5131-5138

  Sharkey, Robert M ^a   McBride, William J ^a   Cardillo, Thomas M ^a   Govindan, Serengulam V ^a   Wang, Yang ^a   Rossi, Edmund A ^a   Chang, Chien Hsing ^a   Goldenberg, David M ^a  

^a IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; DRUG CARRIER; FIRTECAN; IMMUNOGLOBULIN G; IRINOTECAN; SACITUZUMAB GOVITECAN; CAMPTOTHECIN; CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG RELEASE; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENETICS; PANCREATIC NEOPLASMS; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; CAMPTOTHECIN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; HUMANS; IMMUNOCONJUGATES; MICE; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941222227     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0670     Document Type: Article

References (38)

1. Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-A new wave of cancer drugs. Bioorg Med Chem Lett 2014;24: 5357-63.
2. Drachman JG, Senter PD. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. Hematology Am Soc Hematol Educ Program 2013;2013:306-10.
3. Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther 2012;12:873-90.
4. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, et al. Antibodydrug conjugates: an emerging modality for the treatment of cancer. Ann NY Acad Sci 2014;1321:41-54.
5. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. mAbs 2014;6:34-45.
6. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
7. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002;20:3293-301.
8. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010;2:51-63.
9. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61.
10. Moon SJ, Govindan SV, Cardillo TM, D'Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem 2008;51:6916-26.
11. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011;17:3157-69.
12. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Chang C-H, et al. Sacituzumab govitecan (IMMU-132, an anti-Trop-2-SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic and gastic cancers. Bioconjug Chem 2015;26:919-31.
13. Goldenberg DM, Rossi EA, Govindan SV, Cardillo TM, McBride WJ, Zalath M, et al. Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers. J Clin Oncol 32, 2014 (suppl; abstr 3107).
14. Hirose K, Kozu C, Yamashita K, Maruo E, Kitamura M, Hasegawa J, et al. Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett 2012;3:694-8.
15. Morton CL, Wierdl M, Oliver L, Ma MK, Danks MK, Stewart CF, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 2000;60:4206-10.
16. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, et al. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 1998;4: 743-53.
17. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15:1502-10.
18. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002;72:265-75.
19. Yamamoto M, Kurita A, Asahara T, Takakura A, Katono K, Iwasaki M, et al. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep 2008;20:727-30.
20. Zhao H, Lee C, Sai P, Choe YH, Boro M, Pendri A, et al. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization 1. J Org Chem 2000;65:4601-6.
21. Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 2013;12:968-78.
22. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
23. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012;11:1133-42.
24. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61.
25. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase Itargeting drugs. Oncogene 2003;22:7296-304.
26. Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, et al. New Topoisomerase I mutations are associated with resistance to camptothecin. Mol Cancer 2011;10:64.
27. Ashour ME, Atteya R, El-Khamisy SF. Topoisomerase-mediated chromosomal break repair: an emerging player in many games. Nat Rev Cancer 2015;15:137-51.
28. Zhao H, Rubio B, Sapra P, Wu D, Reddy P, Sai P, et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 2008;19:849-59.
29. Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, et al. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer 2013; 119:4223-30.
30. Alemany C. Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor. Curr Oncol Rep 2014;16:367.
31. Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 2014;74:1125-37.
32. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, et al. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol 2013;14:1216-25.
33. Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, et al. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol 2013;31:4060-6.
34. Goldenberg DM, Vahdat LT, Starodub A, Bardia A, Chuang E, Moroose RL, et al. IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results. San Antonio Breast Cancer Symposium 2014:P5-19-08.
35. Bardia A, Starodub A, Moroose RL, Mayer IA, Diamond JR, Chuang E, et al. IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triplenegative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552). In: Proceedings of the San Antonio Breast Cancer Symposium; 2014 Dec 9-13; San Antonio (TX). Abstract nrP5-19-27.
36. Starodub AN, Ocean AO, Shah MA, Guarino MJ, Picozzi VJ, Vahdat LT, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015 May 5. [Epub ahead of print].
37. Starodub AN, Ocean AO, Shah MA, Vahdat LT, Chuang E, Guarino MJ, et al. SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results. Cancer Res 2014;74:abstract CT206.
38. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a new candidate target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015 Jun 18. [Epub ahead of print].